Effects of spironolactone on human blood mononuclear cells: Mineralocorticoid receptor independent effects on gene expression and late apoptosis induction

British Journal of Pharmacology

Volumn 148, Issue 1, 2006, Pages 46-53

  Salling Sønder, Søren Ulrik ^a   Mikkelsen, Marianne ^a   Rieneck, Klaus ^a   Hedegaard, Chris Juul ^a   Bendtzen, Klaus ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Autoimmunity; Cytokines; Gene expression; Immunotherapy; Inflammation; Mineralocorticoid receptors; Pharmacology; Programmed cell death

Indexed keywords

7ALPHA THIOMETHYLSPIRONOLACTONE; ALDOSTERONE; ALDOSTERONE ANTAGONIST; CANRENONE; CCAAT ENHANCER BINDING PROTEIN BETA; CD14 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CYTOKINE; GENE PRODUCT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MINERALOCORTICOID RECEPTOR; MYC PROTEIN; PHYTOHEMAGGLUTININ; PHYTOHEMAGGLUTININ A; PROTEIN; RECEPTOR; SPIRONOLACTONE; STEROID; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CELL PROTECTION; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG RECEPTOR BINDING; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLAMMATION; MALE; MICROARRAY ANALYSIS; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADULT; ALDOSTERONE; ALDOSTERONE ANTAGONISTS; APOPTOSIS; CELLS, CULTURED; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, MINERALOCORTICOID; RNA, MESSENGER; SPIRONOLACTONE;

EID: 33646402048     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706700     Document Type: Article

References (34)

1. ARMANINI, D., WITZGALL, H., STRASSER, T. & WEBER, P.C. (1985). Mineralocorticoid and glucocorticoid receptors in circulating mononuclear leukocytes of patients with primary hyperaldosteronism. Cardiology, 72 (Suppl. 1), 99-101.
2. AUPHAN, N., DIDONATO, J.A., ROSETTE, C., HELMBERG, A. & KARIN, M. (1995). Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science, 270, 286-290.
3. BENDTZEN, K., HANSEN, P.R., RIENECK, K. & THE SPIRONOLACTONE/ARTHRITIS STUDY GROUP. (2003). Spironolactone inhibits production of proinflammatory cytokines, including tumor necrosis factor a and interferon-g, and has potential in the treatment of arthritis. Clin. Exp. Immunol., 134, 151-158.
4. BOURKE, E., CASSETTI, A., VILLA, A., FADLON, E., COLOTTA, F. & MANTOVANI, A. (2003). IL-1beta scavenging by the type II IL-1 decoy receptor in human neutrophils. J. Immunol., 170, 5999-6005.
5. COUETTE, B., MARSAUD, V., BAULIEU, E.E., RICHARD-FOY, H. & RAFESTIN-OBLIN, M.E. (1992). Spironolactone, an aldosterone antagonist, acts as an antiglucocorticosteroid on the mouse mammary tumor virus promoter. Endocrinology, 130, 430-436.
6. CUMMING, D.C. (1990). Use of spironolactone in treatment of hirsutism. Cleve. Clin. J. Med., 57, 285-287.
7. DOGGRELL, S.A. & BROWN, L. (2001). The spironolactone renaissance. Expert Opin. Investig. Drugs, 10, 943-954.
8. GARDINER, P., SCHRODE, K., QUINLAN, D., MARTIN, B.K., BOREHAM, D.R., ROGERS, M.S., STUBBS, K., SMITH, M. & KARIM, A. (1989). Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J. Clin. Pharmacol., 29, 342-347.
9. GARTHWAITE, S.M. & MCMAHON, E.G. (2004). The evolution of aldosterone antagonists. Mol. Cell. Endocrinol., 217, 27-31.
10. HANSEN, P.R., RIENECK, K. & BENUTZEN, K. (2004). Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. Immunol. Lett., 91, 87-91.
11. HOGQUIST, K.A., NETT, M.A., UNANUE, E.R. & CHAPLIN, D.D. (1991). Interleukin 1 is processed and released during apoptosis. Proc. Natl. Acad. Sci. U.S.A., 88, 8485-8489.
12. JANKOWSKI, A., SKOREK-JANKOWSKA, A. & LAMPARCZYK, H. (1996). Simultaneous determination of spironolactone and its metabolites in human plasma. J. Pharm. Biomed. Anal., 14, 1359-1365.
13. KASAMATSU, A., ENDO, Y., UZAWA, K., NAKASHIMA, D., KOIKE, H., HASHITANI, S., NUMATA, T., URADE, M. & TANZAWA, H. (2005). Identification of candidate genes associated with salivary adenoid cystic carcinomas using combined comparative genomic hybridization and oligonucleotide microarray analyses. Int. J. Biochem. Cell Biol., 37, 1869-1880.
14. KLAUBER, N., BROWNE, F., ANAND-APTE, B. & D'AMATO, R.J. (1996). New activity of spironolactone. Inhibition of angiogenesis in vitro and in vivo. Circulation, 94, 2566-2571.
15. KOLLS, J.K. & LINDEN, A. (2004). Interleukin-17 family members and inflammation. Immunity, 21, 467-476.
16. LEE, E.G., BOONE, D.L., CHAI, S., LIBBY, S.L., CHIEN, M., LODOLCE, J.P. & MA, A. (2000). Failure to regulate TNF-induced NF-kB and cell death responses in A20-deficient mice. Science, 289, 2350-2354.
17. LEVENS, D. (2002). Disentangling the MYC web. Proc. Natl. Acad. Sci. U.S.A., 99, 5757-5759.
18. LIU, G., LORAINE, A.E., SHIGETA, R., CLINE, M., CHENG, J., VALMEEKAM, V., SUN, S., KULP, D. & SIANI-ROSE, M.A. (2003). NetAffx: Affymetrix probesets and annotations. Nucleic Acids Res., 31, 82-86.
19. LOMBES, M., BINART, N., DELAHAYE, F., BAULIEU, E.E. & RAFESTIN-OBLIN, M.E. (1994). Differential intracellular localization of human mineralocorticosteroid receptor on binding of agonists and antagonists. Biochem. J., 302, 191-197.
20. LOS, L.E. & COLBY, H.D. (1994). Binding of spironolactone metabolites in vivo to renal mineralocorticoid receptors in guinea pigs. Pharmacology, 48, 86-92.
21. MARTIN, S.J., REUTELINGSPERGER, C.P., MCGAHON, A.J., RADER, J.A., VAN SCHIE, R.C., LAFACE, D.M. & GREEN, D.R. (1995). Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med., 182, 1545-1556.
22. MCALLISTER, F., HENRY, A., KREINDLER, J.L., DUBIN, P.J., ULRICH, L., STEELE, C., FINDER, J.D., PILEWSKI, J.M., CARRENO, B.M., GOLDMAN, S.J., PIRHONEN, J. & KOLLS, J.K. (2005). Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J. Immimol., 175, 404-412.
23. MCINNES, I.B. & GRACIE, J.A. (2004). Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr. Opin. Pharmacol., 4, 392-397.
24. OVERDIEK, H.W., HERMENS, W.A. & MERKUS, F.W. (1985). New insights into the pharmacokinetics of spironolactone. Clin. Pharmacol. Ther., 38, 469-474.
25. PITT, B., ZANNAD, F., REMME, W.J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J. & WITTES, J. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med., 341, 709-717.
26. SCHADT, E.E., LI, C., ELLIS, B. & WONG, W.H. (2001). Feature extraction and normalization algorithms for high-density oligonucleotide gene expression array data. J. Cell Biochem., 84 (Suppl. 37), 120-125.
27. SNYDER, S.R., WANG, J., WARING, J.F. & GINDER, G.D. (2001). Identification of CCAAT displacement protein (CDP/cut) as a locus-specific repressor of major histocompatibility complex gene expression in human tumor cells. J. Biol. Chem., 276, 5323-5330.
28. TAKAMURA, N., MARUYAMA, T., AHMED, S., SUENAGA, A. & OTAGIRI, M. (1997). Interactions of aldosterone antagonist diuretics with human serum proteins. Pharm. Res., 14, 522-526.
29. WALD, D., QIN, J., ZHAO, Z., QIAN, Y., NARAMURA, M., TIAN, L., TOWNE, J., SIMS, J.E., STARK, G.R. & LI, X. (2003). SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat. Immunol., 4, 920-927.
30. WARE, C.F. (2005). Network communications: lymphotoxins, LIGHT, and TNF. Annu. Rev. Immunol., 23, 787-819.
31. WERTZ, I.E., O'ROURKE, K.M., ZHOU, H., EBY, M., ARAVIND, L., SESHAGIRI, S., WU, P., WIESMANN, C., BAKER, R., BOONE, D.L., MA, A., KOONIN, E.V. & DIXIT, V.M. (2004). De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature, 430, 694-699.
32. ZANNAD, F., ALLA, F., DOUSSET, B., PEREZ, A. & PITT, B. (2000). Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation, 102, 2700-2706.
33. ZENNARO, M.C., FARMAN, N., BONVALET, J.P. & LOMBES, M. (1997). Tissue-specific expression of alpha and beta messenger ribonucleic acid isoforms of the human mineralocorticoid receptor in normal and pathological states. J. Clin. Endocrinol. Metab., 82, 1345-1352.
34. ZENNARO, M.C., KEIGHTLEY, M.C., KOTELEVTSEV, Y., CONWAY, G.S., SOUBRIER, F. & FULLER, P.J. (1995). Human mineralocorticoid receptor genomic structure and identification of expressed isoforms. J. Biol. Chem., 270, 21016-21020.